Want to see UTHR full AI Analyst Report?
UTHR Stock Chart & Stats
$528.47
-$0.53(-0.10%)
At close: 4:00 PM EDT
$528.47
-$0.53(-0.10%)
Day’s Range― - ―
52-Week Range$292.34 - $609.35
Previous Close$527.94
Volume431.35K
Average Volume (3M)468.75K
Market Cap
$21.98B
Enterprise Value$22.15K
Total Cash (Recent Filing)$2.66B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)17.7
Beta0.54
Next Earnings
Nov 04, 2026EPS Estimate
6.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)30.23
Shares Outstanding42,446,730
10 Day Avg. Volume369,531
30 Day Avg. Volume468,750
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$655.13Price Target Upside23.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)26.82
Revenue Forecast (FY)$3.24B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetEssentially zero debt and substantial equity (~$6.4B TTM) give United Therapeutics durable financial flexibility. This reduces refinancing risk, supports multi-year R&D and organ-manufacturing builds, and enables opportunistic M&A or commercial investments without pressuring liquidity metrics.
High Margins And Cash GenerationVery high gross and net margins coupled with strong operating and free cash flow indicate persistent earnings quality and cash conversion. That durable cash engine funds clinical programs, factory builds and an expanded sales force, reducing dependence on external financing for multi-year commercialization.
Robust Late-stage Pipeline & FilingsPositive Phase III results plus NDAs/sNDAs and planned device filings create structurally material growth optionality. If approved, new indications (PAH, IPF) and multiple inhalation modalities expand addressable markets and diversify revenue beyond the legacy PAH franchise over the next 12–24+ months.
Bears Say
Sharp TTM Revenue DeclineA near‑50% TTM revenue contraction materially increases base‑line uncertainty for sales and growth modeling. Even with high margins, such a large decline can pressure investment returns, complicate commercial scale economics and make multi-quarter recovery dependent on successful launches and execution.
Competitive Pressure On TyvasoSustained competitive uptake in the inhaled prostacyclin class can permanently constrain Tyvaso pricing, formulary access and market share. This structural threat weakens a core revenue stream and raises the bar for new products to offset lost volume through either superior efficacy or differentiated delivery.
Guidance And Timing UncertaintyManagement's refusal to reaffirm 2026 revenue guidance signals meaningful visibility risk around regulatory timing, launches and commercial translation. Persistent timing uncertainty hampers resource allocation, planning for sales ramp investments, and investor confidence over the medium term.
United Therapeutics News
UTHR FAQ
What was United Therapeutics Corp.’s price range in the past 12 months?
United Therapeutics Corp. lowest stock price was $292.34 and its highest was $609.35 in the past 12 months.
What is United Therapeutics Corp.’s market cap?
United Therapeutics Corp.’s market cap is $21.98B.
When is United Therapeutics Corp.’s upcoming earnings report date?
United Therapeutics Corp.’s upcoming earnings report date is Nov 04, 2026 which is in 90 days.
How were United Therapeutics Corp.’s earnings last quarter?
United Therapeutics Corp. released its earnings results on Aug 05, 2026. The company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.862 by $0.408.
Is United Therapeutics Corp. overvalued?
According to Wall Street analysts United Therapeutics Corp.’s price is currently Undervalued.
Does United Therapeutics Corp. pay dividends?
United Therapeutics Corp. does not currently pay dividends.
What is United Therapeutics Corp.’s EPS estimate?
United Therapeutics Corp.’s EPS estimate is 6.57.
How many shares outstanding does United Therapeutics Corp. have?
United Therapeutics Corp. has 42,446,730 shares outstanding.
What happened to United Therapeutics Corp.’s price movement after its last earnings report?
United Therapeutics Corp. reported an EPS of $7.27 in its last earnings report, beating expectations of $6.862. Following the earnings report the stock price went up 0.064%.
Which hedge fund is a major shareholder of United Therapeutics Corp.?
Currently, no hedge funds are holding shares in UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$655.13 (23.97% Upside)
$655.13 (23.97% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 127.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $150.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.30%
Trailing 12-Months
Company Description
United Therapeutics Corp.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Company Deck
UTHR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced significant near-term commercial challenges with very strong clinical and pipeline momentum. Short-term results (Q2 revenue) came in below expectations and Tyvaso faces competitive pressure, creating uncertainty for 2026 revenue. Offsetting this are multiple highly positive Phase III outcomes, major regulatory filings (ralinepag NDA and Tyvaso IPF sNDA), planned additional filings (DPI and SMI), near-complete enrollment for a large PPF trial, aggressive commercial investments (≈100% sales force expansion), and progress across a differentiated xenotransplantation/organ pipeline. Given the material potential of the recent clinical wins and the company’s execution initiatives that could drive meaningful upside in 2027 and beyond, the positives outweigh the near-term lowlights.View all UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$655.13
▲(23.97% Upside)
Technical Analysis
Ownership Overview
1.97% Insiders
23.34% Mutual Funds
3.58% Other Institutional Investors
41.89% Public Companies and Individual Investors